NCT02296684 2026-01-15
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
Phase 2 Completed
Washington University School of Medicine
Marker Therapeutics, Inc.
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa